Oral selective estrogen receptor depressant,the new anti-breast cancer drug elacestrant
Selective estrogen receptor degrader(SERD)is commonly used in the endocrine therapy of estrogen receptor(ER)positive advanced breast cancer.Elacestrant is a novel oral SERD that is for the treatment of advanced breast cancer with ER-positive and human epidermal growth factor receptor(HER)2-negative.It is more effective than other endocrine therapies and can significantly improve the median progression free survival of patients,and is also effective for breast cancer patients with ER gene α mutations.The launch of elacestrant will provide a more effective treatment option for patients with ER-positive,HER2-negative advanced breast cancer.
NETL
NSTL
万方数据
